Glen J Weiss

US Patent:

20110171323, Jul 14, 2011

Filed:

Jan 8, 2011

Appl. No.:

12/987093

Inventors:

GLEN J. WEISS - Phoenix AZ, US

Assignee:

THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE - Phoenix AZ
SCOTTSDALE HEALTHCARE - Scottsdale AZ

International Classification:

A61K 33/24
G01N 33/574
C12Q 1/68
C40B 30/04
A61K 31/282
A61K 31/366
A61K 31/4375
A61K 31/675
A61K 31/704
A61K 31/437
A61P 35/00

US Classification:

424649, 436501, 506 9, 514492, 514452, 514283, 514110, 514 34, 514282, 435 614

Abstract:

Disclosed herein are methods used in the identification of cancer patients likely or unlikely to respond to systemic chemotherapy, methods of treating cancer patients based upon the identification, and kits that facilitate the identification. The methods and kits involve detecting the expression of specific microRNA.

US Patent:

20120070442, Mar 22, 2012

Filed:

Aug 11, 2008

Appl. No.:

12/672557

Inventors:

Glen Joel Weiss - Phoenix AZ, US
Lynne Bemis - Golden CO, US
Wilber A/ Franklin - Denver CO, US

Assignee:

The Regents of the University of Colorado, a body corporate - Denver CO

International Classification:

A61K 39/395
A61P 35/00
A61K 31/713
A61K 31/7088
C12Q 1/68
A61K 31/5377

US Classification:

4241551, 435 612, 435 611, 5142345, 514 44 A, 514 44 R, 4241741, 435 613

Abstract:

Provided herein are methods for identifying a cancer patient responsive to treatment with an EGFR tyrosine kinase inhibitor. One method comprises obtaining a biopsy from the patient and measuring the number of copies of miR-128in DNA extracted from the biopsy. A patient responsive to EGFR tyrosine kinase inhibitor treatment has a cancer with less than two copies of miR-128DNA. Another method comprises measuring miR-128or miR-128level in a biopsy obtained from the patient and comparing that level to miR-128or miR-128level in a normal tissue sample. A patient responsive to treatment with an EGFR tyrosine kinase inhibitor has a cancer expressing a lower level of miR-128or miR-128relative to normal tissue. Further provided herein are methods for treating cancer in a patient in need thereof. One method comprises measuring the level of miR-128or miR-128in a biopsy obtained from the patient and administering to the patient an EGFR tyrosine kinase inhibitor. Another method comprises measuring the number of copies of miR-128in DNA extracted from a biopsy obtained from the patient and administering to the patient an EGFR tyrosine kinase inhibitor. A further method comprises administering to a cancer patient an EGFR tyrosine kinase inhibitor and an miR-128inhibitor, administering an miR-128a mimic, or administering an miR-128mimic. Also provided herein are compositions used to treat cancer in a patient. The compositions comprise an EGFR tyrosine kinase inhibitor and an miR-128inhibitor (or an miR-128inhibitor), and the cancer is characterized as having 2 or more copies of miR-128DNA at the cellular level.

US Patent:

20120095030, Apr 19, 2012

Filed:

Apr 19, 2010

Appl. No.:

13/264969

Inventors:

Glen Weiss - Phoenix AZ, US

Assignee:

THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE - Phoenix AZ

International Classification:

A61K 31/517
A61P 35/00
C40B 40/06
A61K 31/404
C40B 30/04
C07H 21/00

US Classification:

51426622, 506 9, 536 231, 506 16, 5142664, 514414

Abstract:

Methods of using specific microRNA to identify subjects with non-small cell lung cancer likely or unlikely to respond to treatment with tyrosine kinase inhibitors such as erlotinib, sunitinib, or vandetanib; methods of treating subjects based on identification of said subjects as likely to respond to treatment with tyrosine kinase inhibitors; and kits that facilitate the performance of the methods are disclosed.

US Patent:

20120149586, Jun 14, 2012

Filed:

Aug 14, 2009

Appl. No.:

13/057739

Inventors:

Glen Weiss - Phoenix AZ, US

Assignee:

SCOTTSDALE HEALTHCARE - Scottsdale AZ
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE - Phoenix AZ

International Classification:

C12Q 1/68
C07H 21/04
G01N 21/64
C40B 30/00

US Classification:

506 7, 435 612, 536 2431, 435 611

Abstract:

Disclosed herein are methods of predicting the risk of recurrence of cancer on the basis of the expression of microRNA of the miR-520 family.

US Patent:

20120178093, Jul 12, 2012

Filed:

Jul 29, 2010

Appl. No.:

13/387997

Inventors:

Glen Weiss - Phoenix AZ, US
Seungchan Kim - Phoenix AZ, US
Sara Nasser - Phoenix AZ, US

Assignee:

SCOTTSDALE HEALTHCARE - Scottsdale AZ
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE - Phoenix AZ

International Classification:

C12Q 1/68
G01N 21/64
G01N 33/53

US Classification:

435 612, 436501, 435 61

Abstract:

Methods and kits that use miRNA expression to predict the development of brain metastases in non-small cell lung cancer patients are disclosed.

US Patent:

20120245044, Sep 27, 2012

Filed:

Mar 26, 2012

Appl. No.:

13/430609

Inventors:

Glen J. Weiss - Phoenix AZ, US

Assignee:

TRANSLATIONAL GENOMICS RESEARCH INSTITUTE - Phoenix AZ

International Classification:

C12Q 1/68
C12N 9/16
C40B 30/00
G01N 33/566
C07K 14/47
C07H 21/04

US Classification:

506 7, 530350, 536 235, 435 612, 436501, 435 71, 435 792, 435196

Abstract:

This disclosure provides a biomarker profile, which is linked to cancer cell chemo-resistance. The disclosure further provides methods of diagnosis and theranosis, and screening of new therapeutic agents using these biomarkers in the profile, and kits for employing these methods and compositions.

US Patent:

20110124700, May 26, 2011

Filed:

Feb 19, 2009

Appl. No.:

12/735866

Inventors:

Glen Weiss - Phoenix AZ, US

International Classification:

A61K 31/4045
C12Q 1/68
C40B 30/04
A61P 35/00

US Classification:

514414, 435 6, 506 9

Abstract:

Methods of assessing the sensitivity of a cancer cell to a tyrosine kinase inhibitor are disclosed. Such methods include assessing the expression of miR-497 and correlating reduced expression with sensitivity to the tyrosine kinase inhibitor. Also disclosed are methods of assessing the sensitivity of a cell to a tyrosine kinase inhibitor that includes assessing the expression of FGF1, HOXC10, and/or LHFP. Additionally disclosed are methods of treating patients with tyrosine kinase inhibitors such as sunitinib based on results obtained from the disclosed methods and kits that facilitate the methods.

US Patent:

20210270807, Sep 2, 2021

Filed:

Sep 25, 2019

Appl. No.:

17/256592

Inventors:

- SCOTTSDALE AZ, US
- Rochester MN, US
Glen J. WEISS - Phoenix AZ, US

International Classification:

G01N 33/50

Abstract:

The present invention includes a method for screening one or more agents that modulate Regulatory T cell (Treg) activity, the method comprising the steps of: incubating a population CD4+ cells isolated from human blood peripheral mononuclear cells the CD4+ cells in contact with MoT cells in the presence of the one or more agents suspected of modulating Treg activity; detecting activation of the CD4+ cells without or with the agent; and comparing the activation of the CD4+ cells without or with the agent, wherein a change in activation following incubation with the agent relative to the activation of the PBMCs following incubation without the agent indicates that the agent is a modulator of Treg activity.